The mechanism of Wnt-3a in the imbalance of bone metabolism in ankylosing spondylitis

Author: Senior Product Manager of UA Views：376

Wnt-3a regulates osteoblast differentiation and bone formation by activating the classical Wnt pathway. Recent studies have shown that its expression is abnormal in AS patients and is closely related to disease activity and spinal ossification, providing a new perspective for analyzing bone metabolism disorders in AS.

Recent Advances
Product Information

Recent Advances

I. Research Background of Ankylosing Spondylitis and Wnt-3a

Ankylosing spondylitis (AS) is an autoimmune disease characterized by chronic inflammation and pathological bone formation, with a global incidence of approximately 2% to 5%. Its core pathological contradiction lies in the coexistence of "local excessive ossification" and "systemic bone loss": abnormal bone proliferation in spinal joints leads to ankylosis and limited mobility, while systemic osteoporosis increases the risk of fractures. The molecular mechanism underlying this bone metabolism imbalance is a research hotspot, among which Wnt-3a, a key ligand of the Wnt signaling pathway, has emerged as an important target linking inflammation and bone pathology due to its central role in osteogenesis regulation.

Wnt-3a regulates osteoblast differentiation and bone formation by activating the canonical Wnt pathway. Recent studies have confirmed its abnormal expression in AS patients, which is closely related to disease activity and spinal ossification, providing a new perspective for understanding AS-related bone metabolic disorders.

II. Molecular Characteristics and Signal Activation Mechanism of Wnt-3a

Wnt-3a is a key ligand of the canonical Wnt pathway, containing a conserved cysteine domain and functioning through autocrine or paracrine mechanisms. Its signal activation process involves binding to Frizzled receptors and co-receptors LRP5/6 on the cell membrane to form a ternary complex, which inhibits the activity of GSK-3β and blocks the degradation of β-catenin. The accumulated β-catenin in the cytoplasm enters the nucleus and binds to TCF/LEF transcription factors, initiating the expression of osteogenesis-related genes (such as Runx2 and osteocalcin) and promoting the differentiation of mesenchymal stem cells into osteoblasts.

Meanwhile, Wnt-3a can inhibit osteoblast apoptosis through the PI3K/AKT pathway and enhance mineralization function, serving as an important positive regulator for maintaining bone mass homeostasis under physiological conditions.

III. Mechanism of Wnt-3a-Driven Local Ectopic Ossification in AS

(1) Abnormal Expression of Wnt-3a in AS Patients

Clinical studies have shown that serum Wnt-3a levels in AS patients are significantly higher than those in healthy individuals, and are closely related to disease activity indicators: positively correlated with the Bath Ankylosing Spondylitis Metrology Index (BASMI) and the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS), suggesting its involvement in the progression of spinal ankylosis.

The mRNA and protein expressions of Wnt-3a are significantly upregulated in fibroblast-like synoviocytes and mesenchymal stem cells (MSCs) in lesion sites (such as sacroiliac joint synovium and spinal ligaments). Under inflammatory stimulation, a local high-concentration gradient is formed, providing an initiating signal for ectopic ossification.

(2) Specific Pathways of Ectopic Ossification Induced by Wnt-3a

Promotion of osteogenic differentiation and mineralization: MSCs derived from AS patients show high responsiveness to Wnt-3a. Under its stimulation, alkaline phosphatase (ALP) activity increases, mineralized nodule formation is enhanced, and the expression of osteogenic markers such as Runx2 and Osterix is significantly upregulated, accelerating the differentiation of mesenchymal stem cells into osteoblasts.

Driving ligament ossification: Ectopic ossification of spinal ligaments is a core pathology of AS-related ankylosis. Wnt-3a can induce ligament fibroblasts to express osteogenic phenotypes, shifting their function from collagen synthesis to the secretion of mineralized matrix, ultimately leading to ligament ossification and fusion. The expression levels of Wnt-3a and β-catenin in the yellow ligaments of AS patients are positively correlated with the degree of ossification.

Imbalance of osteogenic-osteoclastic coupling: High concentrations of Wnt-3a inhibit osteoclast differentiation by downregulating RANKL expression, reducing local bone resorption, and exacerbating the imbalance of "excessive osteogenesis and inhibited osteoclasts," accelerating ectopic bone deposition.

IV. Association Between Wnt-3a and Systemic Bone Loss in AS

The systemic bone loss in AS patients (such as reduced bone mineral density in vertebrae and hips) suggests that Wnt-3a may be involved in dual regulation, with possible mechanisms including:

(1) Spatial Heterogeneity of Expression

AS patients exhibit a "local high expression-systemic relative deficiency" distribution pattern of Wnt-3a: lesion sites secrete large amounts under inflammatory stimulation, driving ectopic ossification; while in systemic circulation, it may be relatively insufficient due to local consumption or inhibition by inflammatory factors, weakening systemic osteogenic stimulation.

(2) Indirect Impact on Osteoclast Activity

Insufficient Wnt-3a weakens the ability of osteoblasts to secrete osteoprotegerin (OPG), reducing the inhibition of osteoclasts (OPG can antagonize RANKL). Clinical data show that serum Wnt-3a levels in AS patients with osteoporosis are lower than those without osteoporosis, and negatively correlated with the bone resorption marker TRAP-5b, supporting this mechanism.

V. Interaction Between Wnt-3a and Other Pathways or Inflammatory Factors

(1) Synergy with the BMP Pathway

The bone morphogenetic protein (BMP) pathway has a synergistic effect with the Wnt-3a pathway. In MSCs of AS patients, BMP2 expression is increased while its antagonist Noggin is decreased. Wnt-3a can enhance the activation of Runx2 by BMP2, and conversely, BMP2 can upregulate Wnt-3a expression, forming a positive feedback loop that collectively exacerbates local ossification.

(2) Regulatory Role of Inflammatory Factors

Proinflammatory factors such as IL-17 and TNF-α directly upregulate Wnt-3a transcription in AS synoviocytes by activating the NF-κB pathway; meanwhile, Wnt-3a can promote the secretion of inflammatory factors such as IL-6, forming a "inflammation-Wnt-3a-ossification" vicious cycle, which explains the synchronous progression of inflammatory activity and ossification in AS.

VI. Potential of Wnt-3a as a Diagnostic and Therapeutic Target for AS

(1) Biomarker Value

The close association between Wnt-3a and BASMI, mSASSS makes it a potential biomarker for evaluating AS progression. Dynamic monitoring of serum Wnt-3a levels can predict the risk of spinal ankylosis early, providing a basis for personalized treatment.

(2) Exploration of Therapeutic Strategies

Inhibiting Wnt-3a activity may prevent ectopic ossification, with candidate drugs including neutralizing antibodies and LRP5/6 antagonists. However, systemic inhibition may exacerbate bone loss, so the development of locally targeted delivery systems (such as intra-articular injection formulations) is a future direction to balance efficacy and safety.

VII. Summary and Outlook

Wnt-3a plays a core role in AS-related bone metabolism imbalance: local high expression drives spinal ectopic ossification, while systemic relative deficiency participates in systemic bone loss. Its interaction with the BMP pathway and inflammatory factors further amplifies the pathological effects. In-depth research on its mechanism will provide a theoretical basis for developing AS therapies that simultaneously resist ossification and prevent bone loss, with important clinical transformation value.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next